Chemiluminescence assay platforms

Gastrin-17 (G-17) is applied for the screening, risk stratification, and auxiliary diagnosis of chronic atrophic gastritis, gastric antral mucosal atrophy, and gastric cancer, as well as the non-invasive monitoring of gastric acid status, Helicobacter pylori (H. pylori) infection, and long-term proton pump inhibitor (PPI) therapy. G17 OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct structural epitopes on the G-17 molecule to capture serum or plasma G-17, delivering high sensitivity and exceptional specificity without cross-reactivity to other gastrin isoforms or cholecystokinin (CCK). Calibrated with high-purity recombinant G-17 antigen, the assay provides accurate, reliable, and stable quantitative results. Serving as a crucial non-invasive biomarker for gastric antral secretory function, when combined with PG I, PG II, and the PGI/PGII ratio (PGR) in the "serological gastric biopsy" panel, it supports precise location-specific identification of gastric mucosal lesions, non-invasive gastric cancer risk stratification, and dynamic clinical management.   ★Bulk reagents are available with matching raw materials.                                   

Pepsinogen I (PGI) is applied for the screening, risk stratification, and auxiliary diagnosis of chronic atrophic gastritis and gastric cancer, as well as the non-invasive evaluation of gastric mucosal secretory function and gastric body atrophy. PGI OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct structural epitopes on the PG I molecule to capture serum or plasma PG I, delivering high sensitivity and exceptional specificity without cross-reactivity to Pepsinogen II (PG II). Calibrated with high-purity recombinant PG I antigen, the assay provides accurate, reliable, and stable quantitative results. Serving as a primary non-invasive biomarker for gastric acid secretory capacity, when combined with PG II and the PGI/PGII ratio (PGR), it supports early identification of gastric mucosal atrophy, non-invasive gastric cancer risk stratification, and clinical therapeutic monitoring.   ★Bulk reagents are available with matching raw materials.                                         

Pepsinogen II (PGII) is applied for the screening, risk stratification, and auxiliary diagnosis of chronic atrophic gastritis, peptic ulcer diseases, and gastric cancer, as well as the dynamic monitoring of Helicobacter pylori (H. pylori) eradication therapy and gastric mucosal status. PGII OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct structural epitopes on the PG II molecule to capture serum or plasma PG II, delivering high sensitivity and exceptional specificity without cross-reactivity to Pepsinogen I (PG I). Calibrated with high-purity recombinant PG II antigen, the assay provides accurate, reliable, and stable quantitative results. Serving as a key non-invasive biomarker for gastric health evaluation, when combined with PG I and the PGI/PGII ratio (PGR), it supports early identification of gastric mucosal lesions, non-invasive gastric cancer risk assessment, and clinical therapeutic efficacy monitoring.   ★Bulk reagents are available with matching raw materials.                                           

D-Dimer is applied for the rule-out diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the auxiliary diagnosis, risk evaluation, and dynamic monitoring of disseminated intravascular coagulation (DIC) and hypercoagulable states. D-Dimer OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct cross-linked D-Dimer domain epitopes on fibrin degradation products to capture plasma D-Dimer, delivering high sensitivity and exceptional specificity without cross-reactivity to fibrinogen. Calibrated with high-purity recombinant D-Dimer antigen, the assay provides accurate, reliable, and stable quantitative results. Serving as a crucial clinical biomarker for thrombotic disorders, it supports rapid emergency rule-out, risk assessment, and therapeutic response monitoring in thrombolytic therapy. As a classic thrombosis marker, D-Dimer is widely used clinically to rule out venous thromboembolism (VTE). It also supports diagnosis and therapeutic monitoring of disseminated intravascular coagulation (DIC) and malignant tumors, as well as evaluation of coagulation disorders, making it one of the most commonly ordered coagulation tests by clinicians. ★Bulk reagents are available with matching raw materials.                               

Suppression of Tumorigenicity 2 (ST2) is applied for risk stratification, disease severity evaluation, and prognosis assessment of patients with acute and chronic heart failure, as well as cardiac fibrosis and remodeling. ST2 OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct epitopes on the soluble ST2 molecule to capture plasma sST2, delivering high sensitivity and exceptional specificity. Calibrated with high-purity recombinant sST2, the assay provides accurate, reliable, and stable quantitative results. Unaffected by age, BMI, or renal function, it serves as a valuable novel biomarker for cardiac fibrosis and biomechanical strain, supporting personalized risk prediction and dynamic therapeutic monitoring in heart failure management.   ★Bulk reagents are available with matching raw materials.   

N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) is applied for auxiliary diagnosis, risk stratification, and prognosis assessment of heart failure, as well as the differential diagnosis of cardiogenic and non-cardiogenic dyspnea. NT-proBNP OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct epitopes on non-glycosylated central and terminal regions of the NT-proBNP molecule to capture plasma NT-proBNP, delivering high sensitivity and exceptional specificity. Calibrated with high-purity recombinant NT-proBNP, the assay provides accurate, reliable, and stable quantitative results. Featuring an extended in-vitro half-life and superior stability, it serves as a core biomarker for heart failure management, supporting early identification, clinical triage, and long-term therapeutic monitoring of cardiac dysfunction.   ★Bulk reagents are available with matching raw materials.                   

Brain Natriuretic Peptide (BNP) is applied for auxiliary diagnosis, risk stratification, and prognosis assessment of heart failure, as well as the differential diagnosis of cardiogenic and non-cardiogenic dyspnea. BNP OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct epitopes on N-terminal and C-terminal regions of the BNP molecule to capture plasma BNP, delivering high sensitivity and exceptional specificity. Calibrated with high-purity recombinant BNP, the assay provides accurate, reliable, and stable quantitative results. Serving as a gold-standard biomarker for heart failure management, it supports early identification, clinical triage, and dynamic therapeutic monitoring of cardiac dysfunction.   ★Bulk reagents are available with matching raw materials.                 

Creatine Kinase-MB (CK-MB) is applied for auxiliary diagnosis of acute myocardial infarction and assessment of myocardial injury in patients with suspected cardiovascular diseases.   CK-MB OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target CK-MB epitopes to capture plasma CK-MB, delivering high sensitivity and specificity. Calibrated with high-purity recombinant CK-MB, the assay provides accurate and stable quantitative results. Serving as a classic biomarker for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial damage for clinical auxiliary diagnosis.   Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) formed via post-translational modification. It is predominantly located in cardiomyocytes, with minor distribution in skeletal muscle, intestine, tongue, prostate and uterus. As a key enzyme in myocardial energy metabolism, CK-MB consists of M and B subunits (M for muscle, B for brain), accounting for 15%–30% of total CK activity. As a critical diagnostic biomarker, CK-MB has gained increasing attention, especially in cardiovascular disorders. Studies verify that both CK-MB mass and activity show good sensitivity for cardiac disease diagnosis. CK-MB mass demonstrates superior anti-interference stability compared with CK-MB activity measurement. ★Bulk reagents are available with matching raw materials.     

Myoglobin (MYO) is applied for early screening of acute myocardial infarction and evaluation of striated muscle damage in patients with suspected muscle injury. MYO OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target MYO epitopes to capture trace plasma MYO, delivering high sensitivity and specificity. Calibrated with high-purity recombinant MYO, the assay provides accurate and stable quantitative results. Serving as a vital early biomarker for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial and skeletal muscle injury for clinical auxiliary diagnosis. Myoglobin (MYO) is a protein uniquely present in human striated muscle and exists at low levels in healthy serum. It leaks into circulation when cardiac or skeletal muscle is injured. Thanks to its small molecular size, MYO elevates early: in AMI patients, levels increase 2–3 hours after symptom onset, peak within 7–10 hours and normalize around 24 hours, making MYO a key marker for AMI testing. Serum MYO assay aids diagnosis of myocardial infarction, muscular dystrophy, myocarditis and cardiomyopathy, as well as assessment of treatment response and prognosis. ★Bulk reagents are available with matching raw materials.   

hs-cTnT is applied for early identification of myocardial injury and rapid diagnosis of acute myocardial infarction in patients with chest pain. hs-cTnT OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target cTnT epitopes to capture trace plasma hs-cTnT, delivering high sensitivity and specificity. Calibrated with high-purity recombinant cTnT, the assay provides accurate and stable quantitative results. Serving as a key biomarker for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial injury for clinical auxiliary diagnosis. Cardiac Troponin T (cTnT) is a protein encoded by the TNNT2 gene, also known as cardiac troponin T2, the cardiac isoform of troponin T. Located on thin filaments of striated muscle, cTnT regulates muscle contraction in response to intracellular calcium concentration changes. As a primary specific biomarker of cardiomyocyte injury, it exhibits superior specificity, sensitivity and accuracy for the diagnosis of acute myocardial infarction (AMI) compared with other biomarkers. ★Bulk reagents are available with matching raw materials.   

hs-cTnI kit  is applied for early diagnosis and monitoring of myocardial injury and acute myocardial infarction. hs-cTnI OEM kit utilizes a three-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific antibodies target different cTnI epitopes to capture trace plasma hs-cTnI, delivering high sensitivity and specificity. Calibrated with high-purity recombinant cTnI, the assay provides accurate and stable quantitative results. Serving as the gold standard for acute myocardial infarction diagnosis, it supports early identification and dynamic monitoring of myocardial injury for clinical auxiliary diagnosis. Ischemia and hypoxia induce myocardial degeneration and necrosis, enabling cTnI leakage into circulation. Plasma cTnI surges 3–12 hours after injury and remains elevated for over one week. In MI patients, cTnI rises early, peaks at 18 h, and stays abnormal for 6–8 days. As a universally accepted biomarker, cTnI detects myocardial injury and is the gold standard for AMI diagnosis. ★Bulk reagents are available with matching raw materials.